Abstract
The aim of this study was to investigate whether atorvastatin can ameliorate the uterine microenvironment in diabetes mellitus. Six non-diabetic (control) and 12 diabetic mature female Sprague–Dawley albino rats were used in this study. Diabetes was induced by intraperitoneal injections of 60 mg/kg streptozotocin, and 10 mg/kg/day of oral atorvastatin was administered for 4 weeks via orogastric tubes. The animals were euthanized, and blood samples were collected via cardiac puncture for biochemical analysis. Bilateral hysterectomy was performed for the histopathologic examination. Endometrial gland degeneration and stromal fibrosis scores concomitant with epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) immunoexpressions were analyzed. The endometrial gland degeneration scores, stromal fibrosis scores and VEGF immunoexpression was significantly lower, and the EGFR immunoexpression was significantly higher in the atorvastatin-treated diabetic rats when compared to the non-treated diabetic group, suggesting that atorvastatin ameliorates the uterine microenvironment in diabetes mellitus.
Chinese abstract
本研究的主要目的为探讨阿托伐他汀能否改善糖尿病患者子宫微环境6只非糖尿病(对照)和12只糖尿病成熟雌性SD大鼠被用于这项研究。通过60 mg/kg链脲霉素对大鼠腹腔内注射诱导糖尿病,并按照10 mg/kg/天的剂量灌胃给予口服阿托伐他汀共四周。对大鼠进行安乐死术,通过心脏采血的方式获取血液样本并进行生化分析,行双子宫切除术用作组织病理学检查。同时亦对大鼠子宫内膜腺体退化评分、间质纤维化评分及表皮生长因子受体(EGFR)和血管内皮生长因子(VEGF)的免疫表达进行了分析。与未接受处理糖尿病大鼠组相比,阿托伐他汀组大鼠内膜退化评分,间质纤维化评分及VEGF免疫表达明显降低,而EGFR免疫表达明显升高。说明阿托伐他汀可改善糖尿病大鼠子宫微环境。